Qalamoun Ḥayawiyya was a vector-biotech company headquartered next to the university of Kalamoon in Deir Atiyah in the Levantine Republic. Initially a small research lab, they were nationalised by Tariq Al-Hashim in 176 BFC and given funding to roll out their low cost miltefosine-imidazole booster country wide, which over the next decade eliminated Cutaneous Leishmaniasis from the Republic. They developed a specialisation in ecologics and starting from 155 BFC began receiving both private and public funding to run curlex mosquito gene drives across the region when west nile virus started becoming more prevalent. Qalamoun Ḥayawiyya were privatised and publicly listed in 132 BFC and began focussing on developing digital epidemiology models, these were used to help distribute inhibitors for hemozoin formation and apicoplast DNA replication in the worldwide malaria eradication drive which began in the 110s. They continued to develop environmental biosensing networks, using engineered bacteria as transducers which could be seen by distant hyperspectral cameras to monitor gene spread across an ecosystem. After a number of successful field trials in 90 BFC Bioforge decided to acquired Qalamoun Ḥayawiyya and were permitted to do so in exchange for contracts for supply of high-value irrigated crop variants to the Republic.